A Multi-center, Active Controlled, Randomized, Double-blinded, Parallel, Phase IV Study to Evaluate the Effect of Improving Glycemic Variability of Anagliptin Compared With Sitagliptin in Patients With Type 2 Diabetes Mellitus
Latest Information Update: 02 Nov 2021
At a glance
- Drugs Anagliptin (Primary) ; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms ACACIA
- Sponsors JW Pharmaceutical
Most Recent Events
- 25 Mar 2021 New trial record